Oliver McCammon
Stock Analyst at LifeSci Capital
(4.81)
# 506
Out of 5,014 analysts
87
Total ratings
38%
Success rate
54.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oliver McCammon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | $38 | $6.82 | +457.18% | 11 | Sep 14, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterated: Buy | n/a | $11.93 | - | 16 | Sep 8, 2026 | |
| INBX Inhibrx Biosciences | Reiterated: Buy | $230 | $100.08 | +129.82% | 5 | Sep 8, 2026 | |
| CADL Candel Therapeutics | Reiterated: Buy | $16 | $10.44 | +53.26% | 6 | Aug 14, 2026 | |
| CELC Celcuity | Reiterated: Buy | $165 | $79.52 | +107.49% | 15 | Aug 14, 2026 | |
| AURA Aura Biosciences | Reiterated: Buy | $23 | $6.28 | +266.24% | 10 | Aug 12, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Buy | $15 | $2.75 | +445.45% | 11 | Aug 11, 2026 | |
| JANX Janux Therapeutics | Reiterated: Buy | $60 | $17.28 | +247.22% | 13 | Aug 7, 2026 |
Corbus Pharmaceuticals Holdings
Sep 14, 2026
Reiterated: Buy
Price Target: $38
Current: $6.82
Upside: +457.18%
Monte Rosa Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.93
Upside: -
Inhibrx Biosciences
Sep 8, 2026
Reiterated: Buy
Price Target: $230
Current: $100.08
Upside: +129.82%
Candel Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $16
Current: $10.44
Upside: +53.26%
Celcuity
Aug 14, 2026
Reiterated: Buy
Price Target: $165
Current: $79.52
Upside: +107.49%
Aura Biosciences
Aug 12, 2026
Reiterated: Buy
Price Target: $23
Current: $6.28
Upside: +266.24%
Perspective Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $15
Current: $2.75
Upside: +445.45%
Janux Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $60
Current: $17.28
Upside: +247.22%